Klinik für Neurologie, RKU, Ulm, Leitender Oberarzt Neurologische Klinik, Abteilungsleiter Konservative Epileptologie, Krankenhaus Rummelsberg gGmbH, Rummelsberg, Schwarzenbruck, Germany
Perampanel has recently been approved as an anticonvulsant drug for focal epilepsies. Phase III trials have shown good tolerability, although data regarding effects of high doses of perampanel are not available. Here, we describe the first case of a 34-year-old patient with perampanel intoxication and attempted suicide, in which the recommended daily dose of perampanel was exceeded ten-fold. Clinical signs of the intoxication and possible psychotropic effects are described.